April 24, 2014
Catalyst Announces Initiation of an Expanded Access Program to Provide Firdapse at No Cost to U.S. Patients with Lambert-Eaton Myasthenic Syndrome
In previously published clinical trials, amifampridine has been shown to reduce neuromuscular weakness and symptoms of autonomic dysfunction in LEMS patients while being well tolerated, said Shin J. Oh, MD, Distinguished Professor Emeritus of Neurology, University of Alabama at Birmingham School of Medicine. I am pleased that the company will be able to make its drug available to patients, who need it, while diligently pursuing FDA approval.
- Alternate Title Link: http://www.pharmacychoice.com/news/article.cfm?Article_ID=1195838